Champions Oncology, Inc. CSBR
NASDAQ
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.10% | -16.45% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.10% | -16.45% | |||
| Cost of Revenue | 10.63% | -22.91% | |||
| Gross Profit | 9.58% | -9.06% | |||
| SG&A Expenses | 6.11% | -3.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.95% | -14.27% | |||
| Operating Income | 21.50% | -178.61% | |||
| Income Before Tax | 16.16% | -108.86% | |||
| Income Tax Expenses | -93.60% | 309.52% | |||
| Earnings from Continuing Operations | 36.13% | -139.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.13% | -139.07% | |||
| EBIT | 21.50% | -178.61% | |||
| EBITDA | 52.50% | -229.87% | |||
| EPS Basic | 35.91% | -138.31% | |||
| Normalized Basic EPS | 15.77% | -231.34% | |||
| EPS Diluted | 35.91% | -138.31% | |||
| Normalized Diluted EPS | 15.77% | -231.34% | |||
| Average Basic Shares Outstanding | -0.11% | 0.19% | |||
| Average Diluted Shares Outstanding | -0.11% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||